The study objective was to evaluate steady-state pharmacokinetics and pharmacodynamics
of piperacillin and tazobactam administered by prolonged infusion in obese patients …

The study objective was to evaluate the population pharmacokinetics and
pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in …

Objective: To report pharmacokinetic alterations and optimal dosing of piperacillin/
tazobactam in an obese patient. Case Summary: A 39-year-old morbidly obese (weight 167 …

Study Objective To evaluate the steady‐state pharmacokinetic and pharmacodynamic
parameters of piperacillin in morbidly obese, surgical intensive care patients. Design Open …

The treatment of infections in critically ill obese and morbidly obese patients is challenging
because of the combined physiological changes that result from obesity and critical illness …

Objective: Obesity and critical illness modify pharmacokinetics of antibiotics, but piperacillin-
tazobactam continuous IV infusion pharmacokinetics has been poorly studied in obese …

The objective of this study was to evaluate the steady-state pharmacokinetics and
pharmacodynamics of piperacillin/tazobactam, administered by prolonged infusion, in …

Introduction To enhance the probability of pharmacodynamic target attainment, piperacillin–
tazobactam can be administered as either a continuous or extended-infusion dosage …

Sir, The combination of piperacillin and tazobactam has been shown to be efficacious for the
treatment of intra-abdominal infections, skin and soft tissue infections, bacteraemia and …

Piperacillin-tazobactam is a potent β-lactam/β-lactamase inhibitor antibiotic commonly
prescribed in the intensive care unit setting. Admitted patients often show large variability in …